Pamela Tuxworth

Pamela is a European and UK Patent Attorney and Head of the Biotechnology and Life Sciences Group, one of the biggest Groups of its type in Europe.

She has more than 20 years’ professional experience at J A Kemp. Pamela handles work across a broad range of biotechnology and life sciences subject matter, including antibodies and their uses, oncolytic viruses, vaccines, peptide vaccines, therapeutic RNAs, stem cells, personalised medicine, diagnostics and next generation sequencing. The challenges associated with obtaining patent protection for antibodies are of particular interest to Pamela.

Pamela has an insightful approach and relishes finding commercially relevant solutions to difficult problems. She has substantial experience of contentious proceedings. Pamela has handled many oppositions and appeals relating to a variety of different inventions at the European Patent Office including, in particular, several multi-party oppositions. She has also had extensive involvement in patent litigation, not just in the UK, but also in the US and China. Reflecting all this experience, Pamela is representing the defendants in two of the first revocation actions filed at the Unified Patent Court (UPC). 

Pamela has worked on several high profile biotechnology drugs from inception to beyond commercialisation, working with inventors in drafting patent applications, prosecuting worldwide patent portfolios, carrying out freedom to operate searches, defending patents before at the European Patent Office, and clearing the way by opposing competitors’ patents. Pamela has also been involved in due diligence leading to public listing or acquisition of biotechnology companies.

Pamela’s client base includes large pharmaceutical companies, biotechnology companies and academic institutions, located in the UK, US, Japan and elsewhere. Pamela is a regular visitor to Japan.

Pamela joined J A Kemp in 1999 and became a partner in 2008.

She is recommended by IAM Patent 1000. “Pamela has over 20 years’ experience in biotech and life sciences, and can prosecute patents in the United Kingdom and Europe with confidence and ease. Clients particularly call on her expertise when they proceed with complex applications or a crowded technical landscape. She handles oppositions deftly and strategically, invariably keeping an eye on clients’ business objectives.”